New York – November 3, 2023 – Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer's disease, on its approximately $100 million initial public offering. Partners Eric Blanchard, Peter Byrne and Div Gupta led the Cooley team advising Lexeo.
Lexeo offered a total of 9,090,910 common stock shares, priced at $11 per share, with a 30-day option for the underwriters to purchase up to 1,363,636 additional shares. The listing began trading on the Nasdaq Global Market on November 3, 2023, under the symbol LXEO.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.